Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131718) titled 'Standard-dose or induction-dose radiotherapy combined with adebelimumab and chemotherapy for locally advanced esophageal squamous cell carcinoma: A non-randomized, dual-cohort, phase II clinical trial' on Sept. 6.
Study Type: Interventional study
Study Design:
Non randomized control
Primary Sponsor: The Affiliated Hospital of Qingdao University
Condition:
Esophageal squamous cell carcinoma
Intervention:
Control group:Conventional-dose radiotherapy combined with chemotherapy and immunotherapy simultaneously
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-09-15
Target Sampl...